{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Kodiak Sciences to Unveil Phase 3 DAYBREAK Data Sept. 28 for Wet AMD Drugs", "body_html": "<p><strong>Palo Alto, Calif. -- [CURRENT_DATE] --</strong> Kodiak Sciences Inc. (Nasdaq: KOD) will report topline results from its Phase 3 DAYBREAK study on Monday, September 28, 2026, evaluating two anti-VEGF candidates, Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer), for patients with wet age-related macular degeneration.</p><h5>Kodiak schedules webcast for 8:30 AM Eastern Time on September 28</h5><p>The precommercial retina-focused biotech will host a live webcast accessible via a dedicated link or through the Events and Presentations page on Kodiak's investor relations website. An archived replay will be made available for a limited period following the event.</p><h5>Zenkuda and KSI-501 target a $15 billion anti-VEGF market</h5><p>Zenkuda already carries a BLA-ready profile in diabetic retinopathy and retinal vein occlusion, with wet AMD as an additional indication under study. KSI-501 is being evaluated separately in wet AMD and diabetic macular edema. Both compounds compete for share of the $15 billion global anti-VEGF market spanning retinal vascular diseases.</p><h5>Additional pivotal readouts are scheduled for December 2026 and second-quarter 2027</h5><p>Kodiak's pipeline includes a third late-stage program, KSI-101, a bispecific protein under evaluation in two BLA-facing Phase 3 studies targeting Macular Edema Secondary to Inflammation. Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026, followed by Pivotal Analysis 2 (PEAK+PINNACLE) results in the second quarter of 2027.</p>", "meta_description": "Kodiak Sciences will release Phase 3 DAYBREAK topline results Sept. 28, 2026, for Zenkuda and KSI-501 in wet AMD, targeting a $15B anti-VEGF market.", "seo_keywords": "Kodiak Sciences, Zenkuda, KSI-501, wet AMD, DAYBREAK Phase 3, anti-VEGF, tarcocimab tedromer, retinal disease", "companies": ["Kodiak Sciences Inc."], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["financial_disclosure", "general_news"], "products": ["Zenkuda"], "themes": ["clinical_trials", "regulatory_compliance"], "events": ["DAYBREAK Topline Results Webcast"], "cta_text": "Access the DAYBREAK topline results webcast via Kodiak Sciences' investor relations events page.", "learn_more": "https://ir.kodiak.com/events-and-presentations/events", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}